Multiple Sclerosis Clinical Trials

Showing 901-920 of 5,960 trials

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613

The current study aimed at evaluating the diagnostic performance of \[18F\]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical recurrence of prostate cancer (PCa), using a composite truth standard. Approximately 190 participants were to be enrolled to ensure at least 152 participants were evaluable (i.e. have both an evaluable \[18F\]CTT1057 Positron emission tomography/Computed Tomography (PET/CT) scan imaging and at least one evaluable Composite Truth Standard (CTS) assessment and had not received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and CTS procedures, which were required for the calculation of the co-primary endpoints.

Prostatic NeoplasmsProstate CancerRecurrence

Novartis Pharmaceuticals190 participantsStarted Sep 2021

Sacramento, California, United States • Marseille, France • Marseille, France +10 more locations

COMPLETEDNA

A Pilot Randomized Controlled Trial: CoINTEGRATE

NCT05732285

The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions. The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care.

Neurocognitive DisordersCognitive DysfunctionTraumatic Brain Injury+2 more

University of Michigan15 participantsStarted Sep 2023

Ann Arbor, Michigan, United States

Study of Diagnostic Performance of [18F]CTT1057 in BCR

A Pilot Randomized Controlled Trial: CoINTEGRATE

Related Searches

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Integrated Model for Promoting Parenting and Early School Readiness in Pediatrics

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

A Study of the MIND Diet for Persons With Multiple Sclerosis

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

Accelerated Transcranial Magnetic Stimulation Intervention for Post-Concussion Syndrome

Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Antithrombotic Strategies in Coronary Artery Dilatations and Aneurysms

Relationship Between Cognition, Workforce Participation and Well-Being in Individuals With Multiple Sclerosis

Futibatinib in Patients With Specific FGFR Aberrations

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Medical Nutrition Formulations Enriched With Postbiotics for the Management of Gastrointestinal Disorders

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.